Eikon Therapeutics, Inc. EIKN
Set alert
5.68 USD +0.37 +6.97%
At close · Nov 2
5.68 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
5.21 Day range 5.76
5.01 52-week range 17.40
- YTD
- -62.13%
- 1 year
- -62.13%
- Open
- 5.35
- Prev close
- 5.31
- Mkt cap
- 307.66M
- Vol
- 410.04K
- Avg vol
- 561.63K
- EPS
- -8.51
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.21
- High
- 5.76
2Y chart
Signals (27)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 26, 2026 | 1 week ago |
| RSI: Oversold | Oct 26, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 15, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 13, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bullish | Sep 1, 2026 | 2 months ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 10, 2026 | 3 months ago |
| RSI: Overbought | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | Jun 26, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 17, 2026 | 4 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| SMA: Bullish | May 29, 2026 | 5 months ago |
| SMA: Bearish | May 26, 2026 | 5 months ago |
Newest 20 of 27.
Financials — quick view
EIKN Revenue — quarterly 0
EIKN Net income — quarterly -88.41M
EIKN EPS — quarterly -1.63
News
- Eikon Therapeutics to Participate in Multiple Investor Conferences in November
- Eikon Therapeutics Announces EIK1001 Plus Pembrolizumab And Chemotherapy In First-Line, Stage 4 Non-Small Cell Lung Cancer Demonstrates Durable Effect In Combination With Standard-Of-Care, With Tolerability Profile Supportive Of Systemic Administration In An Outpatient Setting
- Eikon Therapeutics Presents Initial And Updated Data For EIK1003 And Initial Data For EIK1004 And EIK1005 At ESMO 2026; Initial And Updated Cohort Data From Ongoing Phase 1/2 Study Of EIK1003 Continue To Support Potentially Differentiated Profile
- HC Wainwright & Co. Initiates Coverage On Eikon Therapeutics with Buy Rating, Announces Price Target of $23
- Eikon Therapeutics Files Submits Investigational New Drug Application To FDA To Evaluate EIK1006 To Treat Advanced Metastatic Prostate Cancer
Your note
Sign in to keep a note on EIKN — it syncs with the Stock Master app.